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LactateAbstract Introduction: Mitochondrial diseases are a group of inherited disorders caused by
derangement of mitochondrial respiration. MR spectroscopy (MRS) has been shown to detect
abnormal accumulation of lactate in brain parenchyma and CSF in patients with mitochondrial dis-
orders, but the frequency of detection is largely unknown.
Aim of the work: To evaluate the role of brain MR spectroscopy in the assessment of suspected
mitochondrial diseases in the pediatric age group.
Patients and methods: Thirty children with suspected mitochondrial diseases were examined by
MRS. Examination was done using multisection technique and multiple echo times mainly short
(35 ms) and intermediate (144 ms). Mitochondrial disease criteria scoring system was used to con-
ﬁrm the suspected diagnosis.
Results: All patients showed elevated lactate peak with the CSF being the most sensitive (100%).
Among the 30 patients, 26 (86.7%) had elevated levels of blood lactate/pyruvate ratio. Conven-
tional MRI showed highly suggestive features in 15 patients while non speciﬁc ﬁndings were
detected in 11 patients and 4 showed normal appearing brain.
Conclusions: MRS provides a noninvasive tool for the diagnosis of mitochondrial diseases, espe-
cially in children with non speciﬁc ﬁndings on MRI, normal appearing MRI or a normal blood lac-
tate/pyruvate ratio.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.
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Mitochondrial disorders (MDs) are no longer regarded as rare
disorders, and approximately one-third of inherited metabolic
disorders in children are attributable to mitochondrial defects
(1). Mitochondrial disorders (MDs) are a family of genetically
and clinically heterogeneous diseases characterized by defec-
tive energy production. Their heterogeneity is due in part to
the biochemical complexity of mitochondrial respiration and
the fact that two genomes, one mitochondrial and the other
nuclear, encode the subunits of the respiratory chain com-
plexes (2).
Mitochondrial disorders (MDs) manifest in tissues and or-
gans with high-energy demands, with the central nervous sys-
tem (CNS) being the second most frequently affected system
after the muscular system because of its strong dependence
on oxidative phosphorylation (3). CNS manifestations are
found in both syndromic and non-syndromic mitochondrial
disorders with the most common known mitochondrial syn-
dromes include Leigh syndrome, mitochondrial encephalomy-
opathy, lactic acidosis, and stroke like episodes (MELAS),
Kearns–Sayre syndrome (KSS), and Alpers disease (4).
Clinical manifestations of MDs in the pediatric age group
are often nonspeciﬁc because symptoms may arise from any
organ or system. Although recent advances in genetics have
led to the development of diagnostic tools for many MDs, still
most of the patients present with challenging diagnostic dilem-
mas. Therefore, diagnostic conﬁrmation of a MD is based on a
combination of modalities including clinical features, meta-
bolic survey, neuroradiologic ﬁndings, histopathologic analysis
of muscle specimens, and molecular genetic studies (4).
Apart from the clinical, biochemical and morphological
investigations, neuroimaging is of great importance when diag-
nosing mitochondrial disorders with CNS involvement. Since
the study by Barkovich et al. (5), claims that the combination
of deep gray matter and peripheral white matter involvement
in children should suggest a mitochondrial disorder, the ﬁeld
of neuroimaging has witnessed a marked progress. Both struc-
tural MRI and functional brain imaging methods, including
magnetic resonance spectroscopy (MRS), diffusion-weighted
imaging (DWI) and perfusion MRI, have helped greatly to in-
crease our knowledge of mitochondrial disorders by allowing a
non-invasive pathological assessment of the anatomic lesions,
metabolism and hemodynamics of the brain (6).
MRI signal abnormalities, can reveal speciﬁc or ‘signature’
disease features (as in MELAS syndrome), non-speciﬁc fea-
tures or leukodystrophic-like features suggesting a mitochon-
drial disorder, while a structurally normal brain on MRI
may also be found (7,8).
Themost commonknown radiological features ofmitochon-
drial syndromes include bilateral symmetrical signal abnormal-
ities, most frequently in the lentiform (putamenmore often than
globus pallidus) and caudate nuclei, as well as periaqueductal
gray matter, red nuclei and dentate nuclei in Leigh syndrome,
stroke-like lesions which are often transient with the lesions pre-
dominantly affecting the occipital gray matter, yet not conﬁned
to vascular territories in MELAS; and the involvement of the
subcortical U ﬁbers with sparing of the periventricular white
matter in Kearns–Sayre syndrome (KSS) which differentiates
it from most lysosomal and peroxisomal disorders where sub-
cortical regions are only affected late in the disease (9).MRS is an MR-based, non-invasive method to get chemical
information from the brain. The development of proton MRS
(H-MRS) has made it possible to study both normal and
abnormal metabolite concentrations in the pediatric brain at
different developmental stages. These include N-acetyl aspar-
tate (NAA), creatine (Cr), choline (Cho), myoinositol (myo-
I), glutamate, glutamine, and lactate (10).
When oxidative phosphorylation is impaired as in mito-
chondrial diseases, energy metabolism follows the alternative
route of anaerobic glycolysis and produces lactic acid. Lactate
has a chemical shift of 1.33 ppm and presents as a doublet
peak on in vivo H-MRS due to coupling effects (10). Lactate
elevation has been found as the most prominent MRS signal
abnormality in mitochondrial diseases (6).
A consensus mitochondrial disease criteria scoring system
(MDC) has been recently established to facilitate the diagnos-
tic work-up of patients with suspected mitochondrial disorders
(11). MDC is based on a multidisciplinary approach that in-
cludes clinical signs and symptoms, metabolic/imaging studies
and muscle histology. Among these criteria brain magnetic res-
onance imaging (MRI) and brain magnetic resonance spectros-
copy (MRS) examinations play an important role, especially in
children, since MR ﬁndings may inﬂuence the decision to pre-
cede with additional speciﬁc tests such as molecular analysis
(which is not available at every center) or muscle biopsy (which
is an invasive procedure) (8,11).
The aim of this study was to evaluate the role of brain MRS
in the assessment of suspected mitochondrial diseases in the
pediatric age group.
2. Materials and methods
Thirty children with clinically suspected diagnosis of mitochon-
drial disease were referred for MR imaging and MR spectros-
copy between October 2011 and May 2013. Detailed neuro
logical examination and basic laboratory tests were performed
on all patients. The laboratory tests consisted of analysis of arte-
rial blood gas, blood lactate level (normal 3–12 mg/dl), lactate/
pyruvate ratio (normal less than 18) and metabolic surveys
including assays of blood amino acids and urinary organic acids,
with lactate/pyruvate ratio being the main laboratory test which
we depended upon in our analysis.
2.1. MRI imaging
All patients in our study population required sedation or anes-
thesia. Pre-scanning preparation included 3–6 h fasting. MR
imaging and MR spectroscopy examinations were performed
in a single session in most cases with a 1.5-T MR unit (Signa
Horizon 1.5; GE Medical Systems, Milwaukee, WI). T1-
weighted images [echo time (TE)/repetition time (TR) 11 ms/
550 ms], T2-weighted images (TE/TR 93 ms/4000 ms), ﬂuid-
attenuated inversion recovery (FLAIR) (TE/TR/inversion
time 110 ms/10000 ms/2250 ms) and diffusion weighted images
(DWI) (TE/TR: 105 ms/5200 ms) were performed.
Axial and sagittal T1-weighted images were assessed in par-
ticular for the presence of cortical atrophy, agenesis/hypopla-
sia of the corpus callosum, enlargement/dilatation of the
ventricles and/or subarachnoid spaces. Axial and coronal T2-
weighted images, including ﬂuid attenuated inversion recovery
(FLAIR) images, were studied to identify signal intensity
Table 1 Distribution of the studied cases according to
different parameters.
Number %
Age
<1 year 9 30.0
1 – 2 years 13 43.3
> 2 years 8 26.7
Sex
Male 16 53.3
Female 14 46.7
L/P ratio
Normal 4 13.3
Elevated 26 86.7
MRI ﬁndings
Highly Suggestive 15 50
Non speciﬁc 11 36.6
Normal 4 13.3
MRS +ve lactate
MRS +ve Basal ganglia lactate 29 96.7
MRS +ve White matter lactate 19 63.3
MRS +ve CSF lactate 30 100
Role of brain magnetic resonance spectroscopy 525changes mainly within the basal ganglia and cortex. Myelina-
tion was assessed on T1 sequences in children younger than
6 months, T1 and T2 sequences in the age group between
6 months and 1 year and on T2 in children older than 1 year.
Myelination was compared to age-matched healthy controls.
DWI was used to assess the presence of cytotoxic or myelin
edema both showing restricted diffusion.Table 2 Distribution of the studied cases as regards MRS and scor
Group Number
of patients
P
Group IA (13 patients). . .Leigh
+ve BG lactate 13 1
+ve WM lactate 7 5
+ve CSF lactate 13 1
Group IB(1 patient). . .MELAS
+ve BG lactate 1 1
+ve WM lactate 1 1
+ve CSF lactate 1 1
Group IC (1 patient). . .Kearns–Sayre
+ve BG lactate 1 1
+ve WM lactate 1 1
+ve CSF lactate 1 1
Group IIA(5 patients). . .cortical atrophy
+ve BG lactate 5 1
+ve WM lactate 2 4
+ve CSF lactate 5 1
Group IIB (6 patients). . .combined gray and white matter
+ve BG lactate 6 1
+ve WM lactate 6 1
+ve CSF lactate 6 1
Group III (4 patients). . .Normal MRI
+ve BG lactate 3 7
+ve WM lactate 2 5
+ve CSF lactate 4 1According to pattern speciﬁc approach adopted by Barko-
vich, (12) MRI ﬁndings were categorized on the basis of their
predominant location in the brain as follows: lesion predomi-
nance in the basal ganglia; cerebral cortex; white matter; com-
bined gray and white matter; normal MRI features (no deﬁnite
abnormality on conventional MRI basis).
2.2. MR spectroscopy
MR spectra were obtained by using chemical shift imaging
(CSI) with application of a multisection spectroscopic imaging
technique (15-mm section thickness) spin-echo sequence (2300/
280/1) with outer volume suppression. The ﬁeld of view was
24 cm, with 32 · 32 phase-encoding steps, rendering a nominal
voxel size of 0.8 cm3. Water suppression was accomplished
with a single chemical shift selective pulse with a bandwidth
of 110 Hz. Extracranial lipid signals were attenuated by the
use of eight outer volume saturation pulses. The sections were
chosen so that the most caudal section was at the level of the
third ventricle, slightly above the tentorium; the second section
included the lateral ventricles and basal ganglia; the third
section was at the level of the centrum semiovale; and the
top section contained mainly cortical gray matter.
Voxels were sampled using multiple echo times, including
35 ms (short), and 144 ms (intermediate) with repetition times
of 2000 ms.
A volume of interest for MRS was positioned on the axial
MRI with one or multiple regions within the basal ganglia
(whether normal or abnormal), another within the white
matter (whether normal or abnormal) and the last within the
ventricular CSF. All spectra were reviewed with a special inter-
est in lactate level elevation. A peak at 1.33 ppm at a TE ofing results according to different MRI groups.
ercentage Scoring
before MRS
Final score
after MRS
Number of patients
upgraded after MRS
00 10 probable 2 deﬁnite
3.8 3 possible 11 probable
00
00 1 possible 1 probable 6 out of 15 patients (40%)
00
00
00 1 probable 1 probable
00
00
11 out of 11 patients
00 5 possible 5 probable (100%)
0
00
00 6 possible 6 probable
00
00
5 4 possible 3 probable 3 out of 4 patients (75%)
0 1 possible
00
526 A.A. ElBeheiry et al.35 ms, or an inverted doublet at a TE of 144 ms, was used to
diagnose the acquisition of lactate.
We analyzed the MRS ﬁndings in children with suspected
mitochondrial diseases, which were then compared with the re-
sults of MRI done in the same setting and other diagnostic non
radiological methods including blood lactate/pyruvate ratio.2.3. Scoring system
We used the consensus mitochondrial disease criteria (MDC)
scoring system, (11) which evaluates clinical manifestations (I
with maximum 4 points), metabolic and imaging studies (II withFig. 1 2 year old male presenting with extrapyramidal manifestatio
suggestive of Leigh disease: (A) axial T2 showing bilateral symmetrica
with preserved white matter. (B–D) MRS with intermediate TE showin
ganglia and CSF (white arrows in B and D) with no lactate within the w
(possible MD) which has changed into 5 (probable MD) after MRS.another 4 points as maximum), and morphologic or histopatho-
logic criteria (III with maximum 4 points) with the total score of
12.The clinicalmanifestations are subdivided into 3main groups;
IA: muscle symptoms including ophthalmoplegia, exercise intol-
erance and muscle weakness with maximum 2 points, IB: CNS
abnormalities includingdevelopmental delay, seizures, pyramidal
and extrapyramidal signs, also with maximum of 2 points and
lastly IC: multisystem disease including affection of extra CNS
systems as heart, kidney, vision and hearing with maximum of 3
points. The metabolic and imaging studies (class II) include
laboratory abnormalities as elevated serum lactate, lactate/
pyruvate ratio and alanine along with imaging abnormalities
including Leigh like features (sharing with 2 points), stroke likens associated with seizures with normal L/P ratio. MRI features
l hyperintense signal of the caudate, putamina and globus pallidus
g detectable lactate inverted doublet at 1.33 ppm within the basal
hite matter corona radiata (C). This child had pre MRS score of 4
Role of brain magnetic resonance spectroscopy 527manifestations, cortical or cerebellar atrophy, and leukodystro-
phy (each sharing with only one point) as well as abnormal brain
MRS in the formof elevated lactate (also sharingwith one point).
Maximum of 4 points are collected from this class. Histologic
abnormalities (III) including abnormal mitochondria on electron
microscopy could increase the score with 4 points, leading to a
maximal score of 12points (11).A scoreof 1makesmitochondrial
disease unlikely, from 2 to 4makes it possible, from 5 to 7 is com-
parable with a ‘‘probable mitochondrial disorder’’; while score of
8–12 conﬁrms the diagnosis (‘‘deﬁnite mitochondrial disorder’’).
Yet inour studyanddue to the absenceofhistological assessment,
the ﬁnal scorewasoutof 8 (4 from the clinical scoreand4 fromthe
laboratory and neuroimaging score).
3. Results
30 patients ranging from 2 months up to 10 years of age were
included in this study presenting with wide spectrum of clinical
manifestations which were suspected to be sequel to mitochon-
drial disease. Among the 30 patients, 26 (86.7%) had corre-
sponding elevated levels of blood lactate/pyruvate ratio, and
four (13.3%) had normal levels. (Table 1).
Conventional MRI showed three main groups: group (I)
with highly suggestive features included 13 patients with Leigh
like features, one with MELAS appearance and one withFig. 2 1 year old female presenting with right hemiparesis and exerc
suggestive of MELAS: (A) axial T2 FLAIR showing no deﬁnite abnor
mass effect on the left lateral ventricle. (B) DWI showing restricted diff
intermediate TE showing detectable lactate inverted doublet at 1.33 pp
side, and CSF (C–E), respectively. This child had pre MRS score of 4 (pKearns Sayre disease like ﬁndings (total of 15 patients mount-
ing to 50%), group (II) with non speciﬁc features included 11
patients (36.6%); 5 of which with cortical atrophy and 6 with
combined gray and white matter affection while the last group
(III) included 4 patients (13.3%) with normal appearing brain
(Table 1).
All 30 patients showed elevated lactate peak on MRS with
variable degrees according to the site of detection with the CSF
being the most sensitive (100%), followed by the basal ganglia
whether affected or not on MRI(96.7%) and lastly the
white matter whether involved or not on conventional MRI
(63.3%) (Table 1).
Consequently MRS has upgraded the score of considerable
number of patients (20 out of the 30 examined children mount-
ing to 66.6%) with the most considerable effect being noticed
in groups II and III; i.e. those with non speciﬁc or normal
ﬁndings on MRI (Table 2).3.1. Classiﬁcation of patients according to MRI features
3.1.1. Group I (patients with highly suggestive features)
This group included 15 patients, 13 of which with Leigh like
features (group IA), one with MELAS features (group IB)
and one with Kearns–Sayre like picture (group IC).ise intolerance with abnormally elevated L/P ratio. MRI features
mal signal, but tumefactive cortical thickening on the left side with
usion along the left occipito-parietal hemisphere. (C–E) MRS with
m within the affected hemisphere, normal appearing contralateral
ossible MD) which has changed into 5 (probable MD) after MRS.
528 A.A. ElBeheiry et al.3.1.1.1. Group IA: patients with features of Leigh disease
(bilateral symmetrical basal ganglia involvement): (Fig. 1). 13
patients (5 males and 8 females) were included in this group,
most of which presented clinically with extrapyramidal mani-
festations and 10 had elevated Lactate/pyruvate ratio while 3
showed normal ratio. The highest percentage of this group (7
patients) showed bilateral symmetrical involvement of caudate
and putamen followed by bilateral globus pallidus (GP) iso-
lated affection (3 patients), with 2 patients showing involve-
ment of the entire basal ganglia and one with isolated
putaminal involvement. MRS showed elevated lactate peak
(in the form of inverted doublet at 1.33 ppm on intermediate
TE) in the basal ganglia and CSF of all patients (100%) while
only 7 patients (53.8%) showed detectable lactate within the
normal appearing white matter. 10 patients were categorized
as probable and 3 as possible according to the scoring system
prior to MRS. Final post MRS scoring changed the categories
of two patients from probable to deﬁnite (8 points instead of
7), three patients from possible to probable (5 points instead
of 4) while the rest were upgraded into higher probability(from
6 to 7 and from 5 to 6 points). (Table 2).Fig. 3 1 year old male presenting with external ophthalmoplegia com
P ratio. MRI features are suggestive of Kearns–Sayre Syndrome. (A an
T2 hyperintensity involving the subcortical and deep white matter
intermediate TE showing detectable lactate inverted doublet at 1.33 ppm
MRS score of 6 (probable MD) which has changed into 7 (still proba3.1.1.2. Group IB: patient with features of MELAS (stroke like
lesions not conﬁned to vascular territory): (Fig. 2). One
female patient was included in this group, presenting with
acute onset of right hemiparesis along with exercise intoler-
ance and elevated Lactate/pyruvate ratio. MRI showed
abnormal signal involving the cortical and subcortical regions
of the left parieto-occipital cerebral hemisphere along non
vascular territory mainly evident on diffusion weighted
images. MRS in such case showed detectable high lactate
within the affected region together with the normal appearing
basal ganglia, white matter as well as CSF. Pre MRS scoring
was 4 (possible MD) which has upgraded into 5 (probable
MD) after MRS. (Table 2).
3.1.1.3. Group IC: patient with features of Kearns–Sayre disease
(isolated subcortical and peripheral white matter affection
sparing the periventricular white matter): (Fig. 3). One male
patient was included in this group presenting with global
developmental delay (GDD) and seizures combined with exter-
nal ophthalmoplegia. Lactate/pyruvate ratio was elevated.
MRI showed subcortical and deep peripheral white matterbined with developmental delay and seizures along with elevated L/
d B) Axial T2 images showing normal basal ganglia with abnormal
sparing the periventricular white matter. (C and D) MRS with
within the white matter and CSF, respectively. This child had pre
ble MD) after MRS.
Fig. 4 2 year old male presenting with global developmental delay and seizures with elevated L/P ratio and non-speciﬁc MRI features:
(A) axial T2 showing diffuse cortical atrophy with preserved basal ganglia. (B and C) MRS with intermediate TE showing detectable
lactate inverted doublet at 1.33 ppm within the normal appearing basal ganglia and CSF (B and C), respectively. This child had pre MRS
score of 4 (possible MD) which has changed into 5 (probable MD) after MRS.
Role of brain magnetic resonance spectroscopy 529affection sparing the periventricular white matter with normal
basal ganglia. MRS showed elevated lactate peak in the nor-
mal appearing basal ganglia and CSF along with the affected
white matter. Scoring prior to MRS was 6 points matching
with probable and changed into 7 points after MRS, still
within the probable range (Table 2).3.1.2. Group II (patients with non-speciﬁc MRI features)
11 patients were included in this group, 5 of which showed cor-
tical atrophy (group IIA) and the other 6 showed combined
gray (cortical or basal ganglia) and white matter affection.
3.1.2.1. Group IIA: patients with cortical atrophy and normal
basal ganglia: (Fig. 4). 5 patients (3 males and 2 females) were
included in this group, presenting with combination of seizuresand pyramidal signs. Lactate/pyruvate ratio was elevated in 4
patients and normal in one. MRI showed spectrum of
subnormal development to frank atrophic changes manifested
as widening of cortical sulci mainly fronto-temporal with deep-
ening of the gyri and basal cisterns along with supratentorial
ventricular dilatation. MRS of these 5 patients showed ele-
vated lactate peak in the normal appearing basal ganglia and
CSF of all patients while only 2 patients showed detectable lac-
tate within the normal appearing white matter. All patients
were upgraded from possible to probable according to scoring
after MRS (5 points instead of 4) (Table 2).
3.1.2.2. Group IIB: patients with combined gray and white
matter affection: (Fig. 5). 6 male patients were included in this
group, 5 of which presented with global developmental delay
(GDD) and one with post infectious psychomotor regression.
530 A.A. ElBeheiry et al.Lactate/pyruvate ratio was elevated in all patients. MRI
showed subnormal development to frank atrophy with dysmy-
elination in 2 patients, frank atrophic changes along with cys-
tic white matter in another 2 patients with one showing
combination of atrophy, cystic white matter, basal ganglia
and brain stem affection and the last showing frank atrophy
with white matter and brain stem involvement sparing the ba-
sal ganglia. MRS showed elevated lactate peak in the basal
ganglia, affected white matter and CSF of all patients. All pa-
tients were categorized as possible (4 points) prior to MRS and
changed into probable (5 points) after MRS. (Table 2).Fig. 5 2 year old male presenting with pyramidal signs along with
features include; (A and B) axial T2 FLAIR showing diffuse cortica
showing cystic changes with similar changes noted within the basal g
detectable lactate inverted doublet at 1.33 ppm within the white matter
MD) which has changed into 5 (probable MD) after MRS.3.1.3. Group III: patients with normal appearing brain on MRI:
(Fig. 6)
4 patients (3 females and one male) were included in this
group, 3 of which presented with GDD and pyramidal signs
and one with neonatal onset seizures. Lactate/pyruvate ratio
was elevated in all patients. MRI was completely normal for
age. MRS showed elevated lactate peak (in the form of in-
verted doublet at 1.33 ppm on intermediate TE) in the CSF
of all patients while 3 patients showed detectable lactate peak
within the normal appearing basal ganglia and two within thedevelopmental delay and elevated L/P ratio. MRI non-speciﬁc
l atrophy with bilateral symmetrical white matter hyperintensity
anglia bilaterally. (C and D) MRS with intermediate TE showing
and CSF, respectively. This child had pre MRS score of 4 (possible
Fig. 6 2 year old female presenting with global developmental delay and elevated L/P ratio. (A and B), Axial T2 showing normal basal
ganglia and white matter for age. Note terminal zones of myelination at the peritrigonal regions (arrows at B). (C–E)MRSwith intermediate
TE showing detectable lactate inverted doublet at 1.33 ppmwithin the basal ganglia, and CSF (C and E) with no detection within the normal
appearing white matter (D). This child had pre MRS score of 4 (possible MD) which has changed into 5 (probable MD) after MRS.
Role of brain magnetic resonance spectroscopy 531normal appearing white matter. Three patients were upgraded
from possible to probable score (5 instead of 4 points) afterMRS while one remained within the possible range (4 instead
of 3 points) (Table 2).
532 A.A. ElBeheiry et al.4. Discussion
Diagnosis in infants and children with mitochondrial diseases
is a challenge because of the lack of speciﬁc clinical character-
istics, sensitive biochemical markers, and a single algorithm
(13). The CNS is frequently involved in mitochondrial diseases
because of its strong dependence on oxidative metabolism. The
clinical consequences of this involvement are extremely heter-
ogeneous, and in only a few cases does the coincidence of par-
ticular symptoms and signs depict distinct mitochondrial
syndromes as stroke like manifestations in MELAS, and exter-
nal ophthalmoplegia combined with neurological manifesta-
tions in Kearns–Sayre disease (13,14).
Due to its high resolution and absence of ionizing radia-
tion, MRI is considered the corner stone in imaging of inher-
ited neurodegenerative disorders including suspected
mitochondrial diseases, yet due to its wide range of ﬁndings,
MRI alone cannot be the sole imaging modality for deﬁnite
diagnosis in such conditions. In our investigation 15 out of
30 patients mounting to 50% presented with highly suggestive
ﬁndings, 13 of which with Leigh like features, one with
MELAS and one with Kearns Sayre disease. Yet, similar per-
centage (50%) presented with non speciﬁc ﬁndings ranging
from cortical atrophy to leukodystrophy like picture (11 pa-
tients mounting to 36.6%) with even 4 patients (13.3%) show-
ing normal MRI ﬁndings.
Our results are in agreement with the study of Kim et al. (1)
who investigated the role of MRI in 40 children with mito-
chondrial diseases and found 19 to have known syndromes,
19 with non speciﬁc ﬁndings and 2 with normal MRI features.
It is also matching with a more recent study done by Sofou
et al. (6) who studied 66 children having CNS manifestations
of mitochondrial diseases and shown that 8 patients had nor-
mal MRI examinations with more than 50% of the cases with
non speciﬁc ﬁndings. This is supporting the hypothesis that
mitochondrial brain diseases show non speciﬁc MRI features
in considerable number of patients which may lead to false
interpretation.
In mitochondrial disease, disruption of the respiratory
chain and consequent depletion of NAD+ and NADP+ shift
the predominant catabolic metabolism from the Krebs cycle to
anaerobic glycolysis. This in turn produces an accumulation of
pyruvate and its reduced product, lactate (15). In patients who
manifest characteristics suggesting disruption of mitochondrial
respiration and in whom hypoxia and increased CNS demand
for adenosine 50-triphosphate (as with active seizures) can be
excluded, an elevated lactate can be evidence that conﬁrms
the presence of a mitochondrial disorder (15).
Clinically, elevated serum lactate level and lactate/pyruvate
(L/P) ratio is only a fair marker of mitochondrial disease (15).
The serum lactate detection presents low sensitivity in the diagno-
sis of mitochondriopathies because it is transported to the liver
where it is normally re-oxidized intopyruvate. In normal persons,
CSF lactate levels are lower than serum levels, (15) and this
metabolite is not detected by routineMRSneither in brain paren-
chyma nor in CSF. Therefore, the quantiﬁcation of this metabo-
lite in the CSF provides important information about the
presence of anaerobic metabolism in encephalic tissues (4).
In their analysis of 49 children with highly suspected
mitochondrial disorder, Dinopolous et al. (16) found thatserum lactate concentration was normal in 7 of 49 patients,
including three children with Leigh syndrome. Our study agrees
with Dinopolous et al. (16) that normal levels of serum lactate
and L/P ratios cannot rule out mitochondrial diseases, as in our
study lactate/pyruvate ratio was normal in 4 patients (13.3%), 3
of which had MRI features highly suggestive of Leigh disease.
In another study, Nissenkorn et al. (17) have demonstrated
similar sensitivity between the CSF lactate detection by MRS
and other biochemical, genetic, and histopathological markers
of these diseases. This is matching with our results which
showed that MRS lactate in CSF to be the most sensitive mar-
ker in detection of suspected mitochondrial diseases as lactate
was detected in CSF of all patients (100%) including those
with normal levels of serum L/P ratio.
Some authors have demonstrated a higher sensitivity of
MRS compared to conventional MR scans in the detection
of abnormalities in symptomatic patients and individuals at
risk for mitochondrial disease, who still have not developed
neurological deﬁcit (15,16). The frequency of detectable eleva-
tion of lactate on MRS in cases with syndromic MDs or deﬁ-
nite MDs reported in the literature ranges from 62.5% (5 of 8)
(16) to 81.3% (13 of 16) (15). In our case series, all patients
showed elevated lactate peak with difference in degree of
acquisition according to the site of examination ranging from
100% in CSF to 63.3% in white matter (whether affected or
not) with basal ganglia detection reaching 96.7%.
Sensitivity of brain MRS in mitochondrial diseases in our
study was best detected in 4 patients (group III) who had nor-
mal appearing brain on conventional MRI but showed detect-
able lactate peak on MRS which was the sole imaging clue to
guide the route for diagnosing mitochondrial disease. This was
fortiﬁed by applying the scoring system where 3 out of the 4
patients were upgraded from possible into probable grade.
Our study is one of the few studies measuring lactate in nor-
mal appearing brain, yet showing disagreement to the results
of Bianchi et al. (14) and Lin et al. (15), both of which did
not ﬁnd lactate in normal appearing brain examinations. The
lack of this expected metabolite detection may reﬂect not only
an insufﬁcient brain concentration related to the stage of the
disease, but also the failure to probe the proper brain region.
In fact, both studies (14,15) evaluated the brain only, avoiding
the cerebral spinal ﬂuid (CSF). Potentially, this can be a pitfall
because the clearance of lactate into the CSF spaces is slower
than the clearance of lactate produced by brain tissue (18).
Therefore, there may be a longer window for detection of
elevated lactate in CSF which was evident in our study.
Similar sensitivity was also noticed in cases with non
speciﬁc ﬁndings (group II) which have a wide differential
diagnosis but by virtue of MRS, mitochondrial disease was
suspected and highly considered by scoring system in which
all 11 patients included in this group were upgraded from
possible into probable grade.
Although there is difference in percentage of detection, yet
this is in agreement with the study of Sofou et al. (6) who
studied 66 patients with suspected mitochondrial diseases
and found lactate peaks in 15 out of the 66 patients with
non speciﬁc MRI ﬁndings.
Although known mitochondrial syndromes have character-
istic MRI features, yet MRS still have a role in increasing the
speciﬁcity of diagnosis by excluding mimics of mitochondrial
Role of brain magnetic resonance spectroscopy 533diseases as bilirubin toxicity, Wilson disease and disorders of
fat metabolism which may mimic Leigh syndrome in showing
bilateral basal ganglia T2 hyperintensity, yet show no lactate
peaks specially in CSF (10).
All 15 patients included in group I (highly suspected for
being syndromic) showed positive lactate on MRS with 6 cases
upgraded into higher score mounting to 40% of the studied
group (2 from probable into deﬁnite and 4 from possible into
probable). Our results are running parallel to the older studies
of Barkovich et al. (5), Castillo et al. (19), and Wilichowski
et al. (20), who found positive lactate in 100% of their studied
syndromic mitochondrial diseased patients (14 out of 14 pa-
tients). Some difference in percentage of detection was noticed
when compared to more recent study of Lin et al. (15), who
found positive lactate in only 9 out of 29 patients.
The difference in frequency of detection could be attributed
to the fact that the detection of lactate peak on MRS is depen-
dent on the timing or severity of the disease, the location of the
affected tissues and the site of interrogation, lactate level of
CSF, echo times of MRS, and differences in types of MDs.
It is important to stress that detection of lactate by MRS is
not speciﬁc for mitochondrial diseases. Increases in CNS lac-
tate are found in several other pathologic processes, such as
hypoxia, ischemia, neoplasm, and abscess or inﬂammation.
In most cases, however, clinical presentation and MR imaging
appearance would allow unambiguous distinction among the
potential diagnoses (15). To overcome the previous limitation
which was combined by the absence of ﬁnal diagnosis due to
lack of genetic analysis and muscle biopsy, the role of MRS
in the diagnosis of suspected mitochondrial disease was further
fortiﬁed by applying the forementioned scoring system where
20 patients out of 30 were upgraded after MRS, 18 of which
transferred from possible into probable grade and 2 from
probable into deﬁnite grade. Thus although non speciﬁc, and
only sharing with one point in the scoring system, when spec-
troscopic abnormalities appear (in the form of elevated lactate
peak) together with a clinical and laboratory framework prop-
erly suggestive of mitochondrial dysfunction, they could pro-
vide useful additional information regarding such a complex
diagnostic puzzle. As a result, they could contribute to rein-
forcing a diagnostic suspicion and justify further biochemical
or genetic investigation.
5. Conclusion
Clinical diagnosis in children with mitochondriopathies is not
easy because of variable clinical symptoms. MRS examination
is a noninvasive complementary tool for helping to corrobo-
rate the diagnosis of MDs, especially in patients exhibiting sig-
nal changes on the brain MRI and lactate peaks on MRS but a
normal blood lactate level and in those with normal appearing
MRI examinations or presenting with non speciﬁc MRI ﬁnd-
ings. Furthermore, it helps determining whether further
invasive examinations and/or high-cost diagnostic tests such
as muscle biopsy and/or genetic analysis, are needed.
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